ARS Pharmaceuticals, Inc. (NASDAQ: SPRY)

$9.61 ▼ -0.33 (-3.32%)

As of Jun 18, 2026 04:00 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001671858

Market Cap 954.24 Mn

P/E -4.78

P/S 9.64

Div. Yield 0.00

Revenue Growth (1y) (Qtr) 184.47

Add ratio to table...

About

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the commercialization and development of neffy a needle free intranasal epinephrine spray for the emergency treatment of type I allergic reactions including anaphylaxis. The product uses a proprietary formulation of epinephrine combined with the absorption enhancer Intravail to enable low dose nasal delivery that matches the exposure of injectable epinephrine. neffy 2 mg is approved for adults and children weighing 30 kg or more while neffy 1 mg is approved for children aged 4 years...

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the commercialization and development of neffy a needle free intranasal epinephrine spray for the emergency treatment of type I allergic reactions including anaphylaxis. The product uses a proprietary formulation of epinephrine combined with the absorption enhancer Intravail to enable low dose nasal delivery that matches the exposure of injectable epinephrine. neffy 2 mg is approved for adults and children weighing 30 kg or more while neffy 1 mg is approved for children aged 4 years and older who weigh between 15 kg and 30 kg. The therapy has received regulatory approval in the United States the European Union the United Kingdom Japan Australia and China and is under review by Health Canada with a decision expected in 2026. It represents the first approved needle free epinephrine therapy in more than three decades.

Revenue is generated primarily from the sale of neffy to wholesalers and pharmacies as well as from milestone payments and royalties under collaboration agreements with partners such as Alfresa Pediatrix Seqirus and ALK. The company also receives upfront payments and sales based milestones from these agreements which contribute to its overall income. In the United States ARS Pharmaceuticals maintains a direct sales force of 106 representatives targeting high volume prescribers and a co promotion team of approximately 70 representatives working with ALK US to reach pediatricians. The firm supports its sales effort with a direct to consumer marketing campaign that includes streaming television broadcast and cable advertising as well as digital channels and disease awareness initiatives. Additionally the company operates a virtual prescriber platform getneffy.com that allows patients to obtain a prescription online and has launched disease education programs with advocacy groups.

The company operates in a market dominated by epinephrine auto injectors such as EpiPen from Viatris and its generic equivalents from Teva as well as Adrenaclick Auvi Q and Symjepi. ARS Pharmaceuticals differentiates itself with its needle free delivery system which eliminates needle related pain and improves ease of use and portability. Being the first approved nasal spray epinephrine product gives the company a first mover advantage and a protected intellectual property portfolio extending to 2038. Clinical studies show that neffy delivers comparable pharmacodynamic responses to injectable epinephrine with similar reductions in systolic blood pressure and heart rate during allergic reactions. Real world data from the neffy experience program indicated that approximately 90% of patients treated with a single dose during anaphylaxis event achieved symptom control matching the efficacy of traditional injection. The product also avoids needle associated risks such as accidental injection into blood vessels lacerations or caregiver self injury which are reported with auto injector use.

The company serves patients who experience severe allergic reactions and their caregivers as well as healthcare providers including allergists pediatricians and primary care physicians who prescribe the product. Distribution occurs through pharmaceutical wholesalers and retail pharmacies that stock the medication for patient access. As of February 2026 more than 22,500 physicians had prescribed neffy since its launch indicating a growing base of clinical adopters. The firm reports that approximately 93% of commercial insurance plans provide some level of coverage for neffy while 57% offer coverage without prior authorization and eight of 50 state Medicaid programs cover the drug without prior authorization. These coverage statistics help drive patient access and support the commercial rollout in the United States.

Investment thesis

Bull case

The third‑quarter surge in U.S. net product revenue, driven by a 2.5‑fold increase to $31.3 million, demonstrates that Nephi’s pricing and positioning are resonating with both prescribers and patients. New prescriber market share now sits at 10.3 percent, outpacing existing prescribers, which signals a shift in the industry where ease of use and needle‑free delivery are becoming the deciding factors. The company’s direct‑to‑consumer campaign has increased brand awareness from 20 percent to 56 percent, and 80 percent of surveyed patients now feel strongly enough to ask their doctors about Nephi, indicating a growing pipeline of potential prescriptions. Coupled with a 95 percent likelihood to refill among users versus only 30 percent for traditional injectors, the data suggest a durable utilization pattern that will help drive incremental sales and revenue.
Nephi’s penetration into new patient segments—19 percent lapsed users and 7 percent previously untreated—highlights its ability to expand the overall epinephrine market rather than simply taking share from existing competitors. This shift is supported by high patient satisfaction scores, with 87 percent reporting positive impacts on daily and social life, and the company’s ability to capture these segments speaks to unmet needs that injection products have historically failed to address. By addressing needle anxiety and simplifying the device, Nephi is positioned to convert a larger portion of the 2 billion‑dollar U.S. epinephrine market, creating upside as the market continues to grow organically at 6‑8 percent per year. The expansion into new segments also improves the company's gross‑to‑net retention profile, as cash prescriptions drop from 20 percent to 12 percent, reducing discounting pressures and improving profitability.
The global rollout strategy is accelerating, with YERNEPI already in Germany, the United Kingdom, Japan, Canada, and China slated for 2026, and each market presenting distinct but complementary access frameworks. Germany’s uptake has been three times faster than in the United States because of a seamless prescribing process that eliminates prior authorizations, underscoring how administrative friction can accelerate adoption. The UK launch has already generated strong enthusiasm among prescribers, and Japan’s approval in September with an expected 2025 launch will tap into a large and growing allergic disease patient base. Early traction in these markets suggests that Nephi can rapidly scale its commercial model outside the United States, diversifying revenue streams and mitigating U.S. market seasonality risks.
The Phase 2b urticaria program positions Nephi to tap into a $2 million patient U.S. market, with early market research indicating a 60 percent adoption potential among chronic spontaneous urticaria patients. Successful top‑line data in 2026 could add a high‑margin indication to the product portfolio, leveraging existing manufacturing and distribution capabilities while providing a new revenue stream that is less susceptible to seasonal demand swings. The trial is aligned with a patient segment that is already on antihistamines or biologics, suggesting that Nephi could serve as a bridging or rescue therapy, further expanding its utility and prescription frequency. The successful label expansion would also differentiate Nephi from competitors that focus solely on epinephrine, thereby enhancing the company’s competitive moat.

The third‑quarter surge in U.S. net product revenue, driven by a 2.5‑fold increase to $31.3 million, demonstrates that Nephi’s pricing and positioning are resonating with both prescribers and patients. New prescriber market share now sits at 10.3 percent, outpacing existing prescribers, which signals a shift in the industry where ease of use and needle‑free delivery are becoming the deciding factors. The company’s direct‑to‑consumer campaign has increased brand awareness from 20 percent to 56 percent, and 80 percent of surveyed patients now feel strongly enough to ask their doctors about Nephi, indicating a growing pipeline of potential prescriptions. Coupled with a 95 percent likelihood to refill among users versus only 30 percent for traditional injectors, the data suggest a durable utilization pattern that will help drive incremental sales and revenue.
Nephi’s penetration into new patient segments—19 percent lapsed users and 7 percent previously untreated—highlights its ability to expand the overall epinephrine market rather than simply taking share from existing competitors. This shift is supported by high patient satisfaction scores, with 87 percent reporting positive impacts on daily and social life, and the company’s ability to capture these segments speaks to unmet needs that injection products have historically failed to address. By addressing needle anxiety and simplifying the device, Nephi is positioned to convert a larger portion of the 2 billion‑dollar U.S. epinephrine market, creating upside as the market continues to grow organically at 6‑8 percent per year. The expansion into new segments also improves the company's gross‑to‑net retention profile, as cash prescriptions drop from 20 percent to 12 percent, reducing discounting pressures and improving profitability.
The global rollout strategy is accelerating, with YERNEPI already in Germany, the United Kingdom, Japan, Canada, and China slated for 2026, and each market presenting distinct but complementary access frameworks. Germany’s uptake has been three times faster than in the United States because of a seamless prescribing process that eliminates prior authorizations, underscoring how administrative friction can accelerate adoption. The UK launch has already generated strong enthusiasm among prescribers, and Japan’s approval in September with an expected 2025 launch will tap into a large and growing allergic disease patient base. Early traction in these markets suggests that Nephi can rapidly scale its commercial model outside the United States, diversifying revenue streams and mitigating U.S. market seasonality risks.
The Phase 2b urticaria program positions Nephi to tap into a $2 million patient U.S. market, with early market research indicating a 60 percent adoption potential among chronic spontaneous urticaria patients. Successful top‑line data in 2026 could add a high‑margin indication to the product portfolio, leveraging existing manufacturing and distribution capabilities while providing a new revenue stream that is less susceptible to seasonal demand swings. The trial is aligned with a patient segment that is already on antihistamines or biologics, suggesting that Nephi could serve as a bridging or rescue therapy, further expanding its utility and prescription frequency. The successful label expansion would also differentiate Nephi from competitors that focus solely on epinephrine, thereby enhancing the company’s competitive moat.

Bear case

Despite progress, the prior authorization requirement remains a significant bottleneck, with roughly fifty‑percent of covered lives still needing approval for Nephi. Management has offered optimistic timelines for payer negotiations, but no concrete commitments have been secured, and the pathway to unrestricted access is unclear. Until major national payers remove this hurdle, a sizable portion of the potential market will remain inaccessible, limiting the company's ability to achieve the projected sales volumes. The uncertainty surrounding payer coverage could also depress gross‑to‑net retention, as providers may preferentially prescribe competing products that do not trigger authorizations, eroding Nephi’s pricing power.
Seasonal demand cycles pose a persistent risk, as evidenced by the company’s own forecast of a one‑third decline in Q4 sales due to epinephrine market contraction and inventory adjustments. Distributors currently maintain a 15‑to‑20‑day on‑hand inventory, but this buffer can be strained if demand drops more sharply or if supply chain disruptions occur. Over‑inventory in peak periods could lead to markdowns or unsold stock, squeezing margins, while under‑inventory during spikes could result in lost sales and weakened market position. The reliance on seasonal peaks also magnifies the impact of any external events, such as public health disruptions, that could further distort prescribing patterns.
The Get Nephi On Us virtual prescribing program, while innovative, carries several execution risks that are not fully disclosed. Regulatory uncertainty around virtual prescriber models could limit adoption, particularly if payer policies change or if clinical guidelines are updated to favor traditional office visits. Moreover, the program’s success hinges on widespread patient and provider engagement; early reports are encouraging, but the company has not yet demonstrated sustained conversion rates beyond the initial launch. If uptake stalls, the company’s ability to convert lapsed or untreated patients will be compromised, stalling the growth narrative that relies on continuous patient acquisition.
Competitive pressure in the epinephrine market remains intense. Existing products such as conventional injector pens have entrenched brand loyalty and are priced aggressively, and the U.S. market has shown modest organic growth of 6‑8 percent prior to Nephi’s entry. Nephi’s higher gross‑to‑net retention suggests the company can maintain a margin advantage, yet price erosion could occur if competitors launch lower‑cost alternatives or if insurers negotiate tighter rebates. Additionally, the 2 billion‑dollar market value could be overstated if payer coverage restrictions or high out‑of‑pocket costs discourage patient uptake. The company’s ability to sustain growth will depend on maintaining a pricing advantage in a market that is increasingly sensitive to cost and reimbursement dynamics.

Despite progress, the prior authorization requirement remains a significant bottleneck, with roughly fifty‑percent of covered lives still needing approval for Nephi. Management has offered optimistic timelines for payer negotiations, but no concrete commitments have been secured, and the pathway to unrestricted access is unclear. Until major national payers remove this hurdle, a sizable portion of the potential market will remain inaccessible, limiting the company's ability to achieve the projected sales volumes. The uncertainty surrounding payer coverage could also depress gross‑to‑net retention, as providers may preferentially prescribe competing products that do not trigger authorizations, eroding Nephi’s pricing power.
Seasonal demand cycles pose a persistent risk, as evidenced by the company’s own forecast of a one‑third decline in Q4 sales due to epinephrine market contraction and inventory adjustments. Distributors currently maintain a 15‑to‑20‑day on‑hand inventory, but this buffer can be strained if demand drops more sharply or if supply chain disruptions occur. Over‑inventory in peak periods could lead to markdowns or unsold stock, squeezing margins, while under‑inventory during spikes could result in lost sales and weakened market position. The reliance on seasonal peaks also magnifies the impact of any external events, such as public health disruptions, that could further distort prescribing patterns.
The Get Nephi On Us virtual prescribing program, while innovative, carries several execution risks that are not fully disclosed. Regulatory uncertainty around virtual prescriber models could limit adoption, particularly if payer policies change or if clinical guidelines are updated to favor traditional office visits. Moreover, the program’s success hinges on widespread patient and provider engagement; early reports are encouraging, but the company has not yet demonstrated sustained conversion rates beyond the initial launch. If uptake stalls, the company’s ability to convert lapsed or untreated patients will be compromised, stalling the growth narrative that relies on continuous patient acquisition.
Competitive pressure in the epinephrine market remains intense. Existing products such as conventional injector pens have entrenched brand loyalty and are priced aggressively, and the U.S. market has shown modest organic growth of 6‑8 percent prior to Nephi’s entry. Nephi’s higher gross‑to‑net retention suggests the company can maintain a margin advantage, yet price erosion could occur if competitors launch lower‑cost alternatives or if insurers negotiate tighter rebates. Additionally, the 2 billion‑dollar market value could be overstated if payer coverage restrictions or high out‑of‑pocket costs discourage patient uptake. The company’s ability to sustain growth will depend on maintaining a pricing advantage in a market that is increasingly sensitive to cost and reimbursement dynamics.

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ATHE	Alterity Therapeutics Ltd	925,601.88 Bn	-	50.75 Mn	-
2	BLTE	Belite Bio, Inc	58,560.00 Bn	-95.69	-	-
3	QNTM	Quantum Biopharma Ltd.	17,284.41 Bn	0.76	-	-
4	LEGN	Legend Biotech Corp	2,809.00 Bn	0.00	0.00 Mn	319.10 Mn
5	EVAX	Evaxion A/S	1,334.43 Bn	0.00	0.00 Mn	-
6	AKTX	Akari Therapeutics Plc	1,312.27 Bn	-44,753.60	-	-
7	PBM	Psyence Biomedical Ltd.	212.16 Bn	10.84	-	-
8	VRTX	Vertex Pharmaceuticals Inc / Ma	114.83 Bn	26.57	0.00 Mn	-

Research Tools

Developers

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer comparison

Research Tools

Developers

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password